Concurrent Taxol (Paclitaxel) and Definitive Breast Radiation Therapy in Early Stage Breast Cancer Following Four Cycles of Adriamycin/Cytoxan Chemotherapy
- Determine the feasibility of concurrent paclitaxel and breast radiotherapy in women
with stage II or III breast cancer who have had primary breast conserving surgery and
- Assess the cosmetic results of breast conservation after this treatment in these
- Determine the pulmonary toxicity of this regimen in these patients.
OUTLINE: Patients receive paclitaxel IV over 3 hours every 21 days for 4 courses beginning 3
weeks after completion of the last doxorubicin and cyclophosphamide adjuvant regimen.
Patients also undergo concurrent radiotherapy 5 days a week for approximately 6-7 weeks.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed at 1 month, every 3 months for 1 year, every 6 months for the next 5
years, and then annually thereafter.
PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study over 12-18
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine the feasibility of concurrent paclitaxel and breast radiotherapy
Ability to deliver appropriate doses of radiation therapy within the appropriate time course and calculate the chemotherapy dose achieved during concurrent Taxol and radiation therapy.
Followed every 3 months for 1 year
Paula Silverman, MD
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
United States: Federal Government
|Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center||Cleveland, Ohio 44106-5065|
|UH-CantonMercy||Canton, Ohio 44708|
|UH-Geauga||Chardon, Ohio 44024|
|UH-Monarch||Mayfield Heights, Ohio 44124|
|UH-LUICC||Mentor, Ohio 44060|
|UH-Southwest||Middleburgh Heights, Ohio 44130|
|UH-Chagrin Highlands||Orange Village, Ohio 44122|
|UH-Green Road||South Euclid, Ohio 44121|
|UH-Westlake||Westlake, Ohio 44145|